US20030203028A1 - Multiplex drug delivery system suitable for oral administration - Google Patents
Multiplex drug delivery system suitable for oral administration Download PDFInfo
- Publication number
- US20030203028A1 US20030203028A1 US10/435,013 US43501303A US2003203028A1 US 20030203028 A1 US20030203028 A1 US 20030203028A1 US 43501303 A US43501303 A US 43501303A US 2003203028 A1 US2003203028 A1 US 2003203028A1
- Authority
- US
- United States
- Prior art keywords
- hcl
- delivery system
- drug delivery
- multiplex
- active agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
Definitions
- the present invention relates to a single drug delivery unit suitable for oral administration containing at least two distinct drug dosage packages.
- This multiplex system contains at least two immediate-release compartments substantially enveloped by a scored extended-release compartment.
- the scored nature of the extended-release compartment facilitates the separation by the patient of the multiplex drug delivery system into individual drug dosage packages for oral administration of the prescribed dosage.
- each individual drug dosage package can exhibit an equivalent, and preferably identical, release profile for the active agent as compared to one another and to that of the entire multiplex system. Accordingly, in a preferred embodiment, the separability of the multiplex drug delivery system enables its use throughout the entire course of a varying dosage regimen, and thus, facilitates cost effective patient compliance.
- Drug efficacy depends upon the maintenance of the proper therapeutic levels of the drug over the required treatment period. With respect to orally administered drugs, the effectiveness of treatment depends, in part or sometimes in whole, on patient compliance with the prescribed dosage regimen. Particularly where the prescribed dosage increases or decreases during the treatment period, patient compliance can suffer because of the unavailability of, or inconvenience in obtaining, the appropriate dosage of the prescribed medication at different times.
- a valuable contribution to the art therefore would be the development of a multiplex drug delivery system suitable for oral administration containing at least two immediate-release compartments substantially enveloped by a scored extended-release compartment that facilitates the separation of the multiplex drug delivery system into individual drug dosage packages for oral administration of the prescribed dosage, each of which can exhibit an equivalent, and preferably identical, release profile for the active agent as compared to one another and to that of the entire multiplex system.
- an objective of the present invention is a single drug delivery unit suitable for oral administration that patients could separate into individual drug dosage packages.
- These individual drug dosage packages can exhibit an equivalent, and preferably identical, release profile for the active agent when compared to one another or when compared to the entire, intact multiplex drug delivery system.
- the present invention accomplishes this objective through a multiplex drug delivery system suitable for oral administration containing at least two immediate-release compartments.
- the scored extended-release compartment of the invention allows the separation of the multiplex drug delivery system into individual drug dosage packages for oral administration of the prescribed dosage, each of which can exhibit an equivalent, and preferably identical, release profile for the active agent as compared to one another and to that of the entire multiplex system.
- One preferred embodiment of the claimed invention is a multiplex drug delivery system suitable for oral administration comprising at least two immediate-release compartments substantially enveloped by a scored extended-release compartment.
- the extended-release compartment can comprise a combination of a hydrophilic and a hydrophobic material.
- the hydrophilic polymer(s) dissolves away to weaken the extended-release compartment, while the hydrophobic material retards the water, thus helping to preserve the integrity of the drug delivery system.
- the immediate-release compartments are inert (i.e., do not comprise an active agent), they can facilitate a bursting effect, which can disrupt any remaining integrity of the extended-release compartment.
- each immediate-release compartment further comprises an effective amount of an active agent, or a pharmaceutically acceptable salt thereof and the scored extended-release compartment further comprises an effective amount of an active agent, or a pharmaceutically acceptable salt thereof, in a compressed blend with the combination of a hydrophilic polymer and a hydrophobic material.
- each immediate-release compartment further comprises an effective amount of an active agent, or a pharmaceutically acceptable salt thereof, in a compressed blend with a polymer.
- the scored extended-release compartment further comprises an effective amount of an active agent, or a pharmaceutically acceptable salt thereof, in a compressed blend with the combination of a hydrophilic polymer and a hydrophobic material.
- the active agent contained in the multiplex drug delivery system can be a drug.
- that drug can be a therapeutic or a prophylactic drug.
- the drug of the multiplex drug delivery system can be diltiazem, trapidil, urapidil, benziodarone, dipyridamole, isosorbide mononitrate, or lidoflazine.
- the drug can be a non-steroidal antiinflammatory drug (NSAID) or steroidal antiinflammatory drug.
- the steroidal antiinflammatory drug can be diclofenac sodium, ibuprofen, ketoprofen, diflunisal, piroxicam, motrin, or naproxen.
- the drug can be acetaminophen, aldosterone, alprenolol, amitryptyline, aspirin, beclomethasone, diproprionate, bromocriptine, butorphanol tartrate, chlormethiazole, chlorpheniramine, chlorpromazine HCl, cimetidine, codeine, cortisone, cyclobenzamine HCl, desmethylimipramine, dextropropoxyphene, dihydroergotamine, diltiazem HCl, dobutamine HCl, domperidone, dopamine HCl, doxepin HCl, epinephrine, ergoloid mesylates, ergotamine tartrate estradiol, ethinylestradiol, flunisolide, fluorouracil, flurazepam HCl, 5-fluoro-21-deoxyuridine, furosemide, glipizide,
- the active agent can preferably be isosorbide-5-mononitrate.
- the active agent of the multiplex drug delivery system can exhibit the following in vitro dissolution profile when measured in a type 2 dissolution apparatus (paddle) according to U.S. Pharmacopeia XXII at 37° C. ⁇ 0.5° C. in deionized water at 75 rotations per minute:
- the active agent of the multiplex drug delivery system can be isosorbide-5-mononitrate.
- the active agent of the multiplex drug delivery system can exhibit the following in vitro dissolution profile when measured in a type 2 dissolution apparatus (paddle) according to U.S. Pharmacopeia XXII at 37° C. ⁇ 0.5° C. in deionized water at 75 rotations per minute:
- the polymer of the multiplex drug delivery system can be alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium, colloidal silicon dioxide, guar gum, magnesium aluminum silicate, methylcellulose, microcrystalline cellulose, cellulose, pregelatinized starch, sodium alginate, starch, ethylcellulose, gelatin, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polymethacrylates, povidone, shellac, or zein, and preferably hydroxypropyl methylcellulose.
- the hydrophilic polymer of the multiplex drug delivery system can be carboxymethylcellulose, guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose, or povidone, and preferably hydroxypropyl methylcellulose.
- the hydrophobic material of the multiplex drug delivery system can be carnauba wax, ethylcellulose, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, microcrystalline wax, polymethacrylates, or stearic acid, and preferably hydrogenated vegetable oil.
- the present invention also accomplishes these and other objectives through a method for preparing a multiplex drug delivery system suitable for oral administration comprising the steps of: combining an effective amount of an active agent, or a pharmaceutically acceptable salt thereof, and a polymer to form at least two immediate-release compartments; combining an effective amount of an active agent, or a pharmaceutically acceptable salt thereof, and a hydrophilic polymer and a hydrophobic material to form an extended-release compartment; press coating the extended-release compartment to substantially envelop the at least two immediate-release compartments, and scoring the extended-release compartment such that the immediate-release compartments are separable.
- the method for preparing a multiplex drug delivery system suitable for oral administration can include combining by blending, perforated pan coating, fluidized particle coating, wet granulation, fluid-bed granulation, or dry granulation according to methods recognized in the art.
- FIG. 1 is a schematic of one preferred embodiment of the multiplex drug delivery system suitable for oral administration, which contains two immediate-release compartments substantially enveloped by a scored extended-release compartment.
- the scored extended-release compartment of the invention allows the separation of the multiplex drug delivery system into individual drug dosage packages for oral administration of the prescribed dosage, each of which can exhibit an equivalent, and preferably identical, release profile for the active agent as compared to one another and to that of the entire multiplex system.
- the multiplex system consists of an oblong tablet scored in the middle to allow for easy breaking of the tablet.
- Each half of the tablet contains an immediate-release compartment located concentrically within the round tablet edges, allowing for a slightly thicker wall from the center edge when the tablet is broken in half.
- the distance between immediate-release compartments need not be greater than twice the distance between the interface of the immediate-release and extended-release compartments and that of the extended-release compartment and the outer surface or optional cosmetic compartment, so long as once separated, each individual drug dosage package can exhibit an equivalent, and preferably identical, release profile for the active agent as compared to one another and to that of the entire multiplex system.
- FIG. 2 is a graph showing the in vitro dissolution profile (% dissolved versus time) of isosorbide mononitrate extended release tablets (Lots 127-19A and 127-19B), according to an embodiment of the present invention, in deionized water using a type 2 dissolution apparatus (paddle method) at 37 ⁇ 0.5° C. at 75 rotations per minute (rpm). See U.S. Pharmacopeia XXII ⁇ 711> Dissolution.
- FIG. 3 is a graph showing the in vitro dissolution profiles (% dissolved versus time) of an entire multiplex drug delivery system containing two immediate-release compartments (each comprising the active agent isosorbide mononitrate) (Lot 127-19A “whole tablet”), and an individual drug dosage package thereof after separation (Lot 127-19A “half tablet”), according to respective embodiments of the present invention, in deionized water using a type 2 dissolution apparatus (paddle method) at 37 ⁇ 0.5° C. at 75 rotations per minute (rpm). See U.S. Pharmacopeia XXII ⁇ 711> Dissolution.
- active agent includes one or more drugs, their pharmaceutically acceptable salts, pro-drug forms, metabolites, and derivatives.
- Active agents include therapeutic or prophylactic compounds as described in the Physicians' Desk Reference, most preferably including (but not limited to) those prescribed for the prevention and/or treatment of angina and hypertension: diltiazem, trapidil, urapidil, benziodarone, dipyridamole, isosorbide mononitrate, and lidoflazine; and those prescribed for the prevention and/or treatment of rheumatic diseases such as rheumatoid arthritis: non-steroidal antiinflammatory drugs (NSAIDs) and steroidal antiinflammatory drugs such as diclofenac sodium, ibuprofen, ketoprofen, diflunisal, piroxicam, motrin, and naproxen, and combinations thereof.
- NSAIDs non-steroidal antiinflammatory drugs
- steroidal antiinflammatory drugs such as diclofenac sodium, ibuprofen, ketoprofen, diflunisal, piroxicam, motrin, and naproxen, and combinations thereof.
- the active agent of the present invention also preferably includes drugs that are subject to the first pass effect.
- drugs include (but are not limited to) acetaminophen, aldosterone, alprenolol, amitryptyline, aspirin, beclomethasone, diproprionate, bromocriptine, butorphanol tartrate, chlormethiazole, chlorpheniramine, chlorpromazine HCl, cimetidine, codeine, cortisone, cyclobenzamine HCl, desmethylimipramine, dextropropoxyphene, dihydroergotamine, diltiazem HCl, dobutamine HCl, domperidone, dopamine HCl, doxepin HCl, epinephrine, ergoloid mesylates, ergotamine tartrate estradiol, ethinylestradiol, flunisolide, fluorouracil, flu
- the active agent may include the drug, isosorbide-5-mononitrate, an organic nitrate, which is a vasodilator with effects on both arteries and veins.
- the empirical formula is C 6 H 9 NO 6 and the molecular weight is 191.14.
- the chemical name for isosorbide mononitrate is 1,4:3,6-dianhydro-D-glucitrol 5-nitrate.
- Isosorbide mononitrate is the major active metabolite of isosorbide dinitrate and most of the clinical activity of the dinitrate can be attributable to the mononitrate.
- a principal pharmacological action of isosorbide mononitrate is relaxation of vascular smooth muscle and consequent dilatation of peripheral arteries and veins, especially the latter. Dilatation of the veins is known to promote peripheral pooling of blood and decrease venous return to the heart, thereby reducing left ventricular and diastolic pressure and pulmonary capillary wedge pressure (preload). Arteriolar relaxation reduces systemic vascular resistance, systolic arterial pressure, and mean arterial pressure (afterload). Dilation of the coronary arteries also occurs. The relative importance of preload reduction, afterload reduction, and coronary dilatation remains undefined. The mechanism by which isosorbide mononitrate relieves angina pecteria is not fully understood.
- Isosorbide mononitrate is rapidly and completely absorbed from the gastrointestinal tract. In humans, isosorbide mononitrate is not subject to first pass metabolism in the liver. The overall elimination half-life of isosorbide mononitrate is about 6 hours. The rate of clearance is the same in healthy young adults, and in patients with various degrees of renal, hepatic, or cardiac dysfunction.
- polymer includes single or multiple polymeric substances, which can swell, gel, degrade or erode on contact with an aqueous environment (e.g., water), such as one or more of alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium, colloidal silicon dioxide, guar gum, magnesium aluminum silicate, methylcellulose, microcrystalline cellulose, cellulose, pregelatinized starch, sodium alginate, starch, ethylcellulose, gelatin, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polymethacrylates, povidone, pregelatinized starch, shellac, and zein, and combinations thereof.
- an aqueous environment e.g., water
- the “hydrophilic polymers” of the present invention include one or more of carboxymethylcellulose, guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose, and povidone.
- the “hydrophobic materials” of the present invention include one or more of carnauba wax, ethylcellulose, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, microcrystalline wax, polymethacrylates, and stearic acid.
- Isosorbide mononitrate was first mixed with silicon dioxide in a Patterson-Kelley V-blender together with microcrystalline cellulose, croscarmellulose sodium, and magnesium stearate for 15 minutes.
- the powder blend was then compressed using a Manesty Dry-cota with a ⁇ fraction (3/16) ⁇ ′′ diameter, round, flat-face punch and die set. The hardness of the tablets were maintained at 4 ⁇ 2 kp.
- Immediate-Release Compartment Plus Extended-Release Compartment Isosorbide mononitrate was mixed with silicon dioxide in a Patterson-Kelley V-blender together with hydroxypropyl methylcellulose 2208, microcrystalline cellulose, hydrogenated vegetable oil, and magnesium stearate for 15 minutes.
- the core tablets were press-coated using a Korsch Core Coater ⁇ fraction (5/16) ⁇ ′′ ⁇ 3 ⁇ 4′′ capsule shape punches. The hardness of the tablets were maintained at 12 ⁇ 4 kp.
- the formulation of respective release compartments can occur by appropriate granulation methods.
- wet granulation solutions of the binding agent (polymer) are added with stirring to the mixed powders.
- the powder mass is wetted with the binding solution until the mass has the consistency of damp snow or brown sugar.
- the wet granulated material is forced through a sieving device.
- Moist material from the milling step is dried by placing it in a temperature controlled container. After drying, the granulated material is reduced in particle size by passing through a sieving device. Lubricant is added, and the final blend is then compressed.
- particles of inert material and/or active agent are suspended in a vertical column with a rising air stream. While the particles are suspended, the common granulating materials in solution are sprayed into the column. There is a gradual particle buildup under a controlled set of conditions resulting in tablet granulation. Following drying and the addition of lubricant, the granulated material is ready for compression.
- the active agent, diluent, and lubricant are blended and compressed into large tablets.
- the compressed large tablets are comminuted through the desirable mesh screen by sieving equipment. Some more lubricant is added to the granulated material and blended gently. The material is then compressed into tablets.
Abstract
Description
- The present invention relates to a single drug delivery unit suitable for oral administration containing at least two distinct drug dosage packages. This multiplex system contains at least two immediate-release compartments substantially enveloped by a scored extended-release compartment. The scored nature of the extended-release compartment facilitates the separation by the patient of the multiplex drug delivery system into individual drug dosage packages for oral administration of the prescribed dosage. Upon separation, each individual drug dosage package can exhibit an equivalent, and preferably identical, release profile for the active agent as compared to one another and to that of the entire multiplex system. Accordingly, in a preferred embodiment, the separability of the multiplex drug delivery system enables its use throughout the entire course of a varying dosage regimen, and thus, facilitates cost effective patient compliance.
- Drug efficacy depends upon the maintenance of the proper therapeutic levels of the drug over the required treatment period. With respect to orally administered drugs, the effectiveness of treatment depends, in part or sometimes in whole, on patient compliance with the prescribed dosage regimen. Particularly where the prescribed dosage increases or decreases during the treatment period, patient compliance can suffer because of the unavailability of, or inconvenience in obtaining, the appropriate dosage of the prescribed medication at different times.
- It would therefore be beneficial for patients to have one drug delivery unit that allows patients themselves to regulate the amount of drug to administer. Such a capability would enable patients to use the same drug delivery unit throughout their entire treatment period even where their prescribed dosage changes during that time. Patients in such circumstances would have the convenience and cost effectiveness of obtaining in one unit and at the same time the different dosages of their prescribed drug that would be needed during their treatment period.
- A valuable contribution to the art therefore would be the development of a multiplex drug delivery system suitable for oral administration containing at least two immediate-release compartments substantially enveloped by a scored extended-release compartment that facilitates the separation of the multiplex drug delivery system into individual drug dosage packages for oral administration of the prescribed dosage, each of which can exhibit an equivalent, and preferably identical, release profile for the active agent as compared to one another and to that of the entire multiplex system.
- Accordingly, an objective of the present invention is a single drug delivery unit suitable for oral administration that patients could separate into individual drug dosage packages. These individual drug dosage packages can exhibit an equivalent, and preferably identical, release profile for the active agent when compared to one another or when compared to the entire, intact multiplex drug delivery system.
- The present invention accomplishes this objective through a multiplex drug delivery system suitable for oral administration containing at least two immediate-release compartments. The scored extended-release compartment of the invention allows the separation of the multiplex drug delivery system into individual drug dosage packages for oral administration of the prescribed dosage, each of which can exhibit an equivalent, and preferably identical, release profile for the active agent as compared to one another and to that of the entire multiplex system.
- One preferred embodiment of the claimed invention is a multiplex drug delivery system suitable for oral administration comprising at least two immediate-release compartments substantially enveloped by a scored extended-release compartment. The extended-release compartment can comprise a combination of a hydrophilic and a hydrophobic material. In such an embodiment, the hydrophilic polymer(s) dissolves away to weaken the extended-release compartment, while the hydrophobic material retards the water, thus helping to preserve the integrity of the drug delivery system. Where the immediate-release compartments are inert (i.e., do not comprise an active agent), they can facilitate a bursting effect, which can disrupt any remaining integrity of the extended-release compartment.
- In another preferred embodiment of the claimed invention, each immediate-release compartment further comprises an effective amount of an active agent, or a pharmaceutically acceptable salt thereof and the scored extended-release compartment further comprises an effective amount of an active agent, or a pharmaceutically acceptable salt thereof, in a compressed blend with the combination of a hydrophilic polymer and a hydrophobic material.
- In a further preferred embodiment, each immediate-release compartment further comprises an effective amount of an active agent, or a pharmaceutically acceptable salt thereof, in a compressed blend with a polymer. In one other preferred embodiment, the scored extended-release compartment further comprises an effective amount of an active agent, or a pharmaceutically acceptable salt thereof, in a compressed blend with the combination of a hydrophilic polymer and a hydrophobic material. By varying the composition of the polymer(s) in the immediate-release compartments and/or the relative composition of the hydrophilic polymer and hydrophobic material in the extended-release compartment, the respective time periods for the dissolution of the active agent or the bursting effect can be adjusted.
- In a preferred embodiment of the claimed invention, the active agent contained in the multiplex drug delivery system can be a drug. In other embodiments, that drug can be a therapeutic or a prophylactic drug.
- In one preferred embodiment of the claimed invention, the drug of the multiplex drug delivery system can be diltiazem, trapidil, urapidil, benziodarone, dipyridamole, isosorbide mononitrate, or lidoflazine. In another embodiment, the drug can be a non-steroidal antiinflammatory drug (NSAID) or steroidal antiinflammatory drug. In an embodiment, the steroidal antiinflammatory drug can be diclofenac sodium, ibuprofen, ketoprofen, diflunisal, piroxicam, motrin, or naproxen. In yet another embodiment, the drug can be acetaminophen, aldosterone, alprenolol, amitryptyline, aspirin, beclomethasone, diproprionate, bromocriptine, butorphanol tartrate, chlormethiazole, chlorpheniramine, chlorpromazine HCl, cimetidine, codeine, cortisone, cyclobenzamine HCl, desmethylimipramine, dextropropoxyphene, dihydroergotamine, diltiazem HCl, dobutamine HCl, domperidone, dopamine HCl, doxepin HCl, epinephrine, ergoloid mesylates, ergotamine tartrate estradiol, ethinylestradiol, flunisolide, fluorouracil, flurazepam HCl, 5-fluoro-21-deoxyuridine, furosemide, glipizide, glyburide, glyceryl trinitrate, guanethidine sulfate, hydralazine HCl, imipramine HCl, indoramin, isoethorine HCl, isoethrine mesylate, isoprenaline, isoproterenol sulfate, isosorbide dinitrate, levallorphan tartrate, levodopa, lidocaine HCl, lignocaine, lorcainide, meperidine HCl, 6-mercaptopurine, metaproterenol sulfate, methoxamine HCl, methylphenidate, methylpreonisolone, methyltestosterone mesylate, metoclopramide, metoprolol tartrate, morphine sulfate, nalbuphine HCl, naloxone HCl, neostigmine, nifedipine, nitrendipine, nitroglycerin, norepinephrine bitartrate, norethindrone, nortriptylene HCl, oxprenolol, oxyphenbutazone, penicillamine, pentazocine HCl, pentazocine lactate, pentobarbital, petnidine, phenacetin, phentolamine HCl, phentolamine mesylate, phenylephrine HCl, phenylephrine bitartrate, phenytoin, pindolal, prazosin, prednisone, progesterone, propoxyphene HCl, propoxyphene napsylate, propranolol HCl, quinidine, reserpine, ritodrine HCl, salicylamide, salbutamol, secobarbital, testosterone, terbutaline, timolol maleate, tolbutamide, or verapamil HCl.
- In one other preferred embodiment of the claimed invention, the active agent can preferably be isosorbide-5-mononitrate.
- In a preferred embodiment, the active agent of the multiplex drug delivery system can exhibit the following in vitro dissolution profile when measured in a
type 2 dissolution apparatus (paddle) according to U.S. Pharmacopeia XXII at 37° C.±0.5° C. in deionized water at 75 rotations per minute: - from about 0% to about 90% of said active agent is released between 1 hour and 16 hours of measurement in said apparatus; and
- from about 0% to about 100% of said active agent is released between 1.5 hours and 28 hours after measurement in said apparatus.
- In such a preferred embodiment, the active agent of the multiplex drug delivery system can be isosorbide-5-mononitrate.
- In still another preferred embodiment, the active agent of the multiplex drug delivery system can exhibit the following in vitro dissolution profile when measured in a
type 2 dissolution apparatus (paddle) according to U.S. Pharmacopeia XXII at 37° C.±0.5° C. in deionized water at 75 rotations per minute: - from about 10% to about 75% of said active agent is released between 1 hour and 5 hours of measurement in said apparatus; and
- no less than about 90% of said active agent is released after 6 hours of measurement in said apparatus.
- In one preferred embodiment of the claimed invention, the polymer of the multiplex drug delivery system can be alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium, colloidal silicon dioxide, guar gum, magnesium aluminum silicate, methylcellulose, microcrystalline cellulose, cellulose, pregelatinized starch, sodium alginate, starch, ethylcellulose, gelatin, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polymethacrylates, povidone, shellac, or zein, and preferably hydroxypropyl methylcellulose.
- In yet another preferred embodiment, the hydrophilic polymer of the multiplex drug delivery system can be carboxymethylcellulose, guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose, or povidone, and preferably hydroxypropyl methylcellulose.
- In a preferred embodiment of the claimed invention, the hydrophobic material of the multiplex drug delivery system can be carnauba wax, ethylcellulose, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, microcrystalline wax, polymethacrylates, or stearic acid, and preferably hydrogenated vegetable oil.
- The present invention also accomplishes these and other objectives through a method for preparing a multiplex drug delivery system suitable for oral administration comprising the steps of: combining an effective amount of an active agent, or a pharmaceutically acceptable salt thereof, and a polymer to form at least two immediate-release compartments; combining an effective amount of an active agent, or a pharmaceutically acceptable salt thereof, and a hydrophilic polymer and a hydrophobic material to form an extended-release compartment; press coating the extended-release compartment to substantially envelop the at least two immediate-release compartments, and scoring the extended-release compartment such that the immediate-release compartments are separable.
- In a preferred embodiment, the method for preparing a multiplex drug delivery system suitable for oral administration can include combining by blending, perforated pan coating, fluidized particle coating, wet granulation, fluid-bed granulation, or dry granulation according to methods recognized in the art.
- Other objects, features and advantages of the present invention will become apparent from the following detailed description. The detailed description and the specific examples, however, indicate only preferred embodiments of the invention. Various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.
- FIG. 1 is a schematic of one preferred embodiment of the multiplex drug delivery system suitable for oral administration, which contains two immediate-release compartments substantially enveloped by a scored extended-release compartment. The scored extended-release compartment of the invention allows the separation of the multiplex drug delivery system into individual drug dosage packages for oral administration of the prescribed dosage, each of which can exhibit an equivalent, and preferably identical, release profile for the active agent as compared to one another and to that of the entire multiplex system.
- In this preferred embodiment, the multiplex system consists of an oblong tablet scored in the middle to allow for easy breaking of the tablet. Each half of the tablet contains an immediate-release compartment located concentrically within the round tablet edges, allowing for a slightly thicker wall from the center edge when the tablet is broken in half. The distance between immediate-release compartments need not be greater than twice the distance between the interface of the immediate-release and extended-release compartments and that of the extended-release compartment and the outer surface or optional cosmetic compartment, so long as once separated, each individual drug dosage package can exhibit an equivalent, and preferably identical, release profile for the active agent as compared to one another and to that of the entire multiplex system.
- FIG. 2 is a graph showing the in vitro dissolution profile (% dissolved versus time) of isosorbide mononitrate extended release tablets (Lots 127-19A and 127-19B), according to an embodiment of the present invention, in deionized water using a
type 2 dissolution apparatus (paddle method) at 37±0.5° C. at 75 rotations per minute (rpm). See U.S. Pharmacopeia XXII <711> Dissolution. - FIG. 3 is a graph showing the in vitro dissolution profiles (% dissolved versus time) of an entire multiplex drug delivery system containing two immediate-release compartments (each comprising the active agent isosorbide mononitrate) (Lot 127-19A “whole tablet”), and an individual drug dosage package thereof after separation (Lot 127-19A “half tablet”), according to respective embodiments of the present invention, in deionized water using a
type 2 dissolution apparatus (paddle method) at 37±0.5° C. at 75 rotations per minute (rpm). See U.S. Pharmacopeia XXII <711> Dissolution. - In accordance with the present invention, the term “active agent” includes one or more drugs, their pharmaceutically acceptable salts, pro-drug forms, metabolites, and derivatives.
- Active agents include therapeutic or prophylactic compounds as described in the Physicians' Desk Reference, most preferably including (but not limited to) those prescribed for the prevention and/or treatment of angina and hypertension: diltiazem, trapidil, urapidil, benziodarone, dipyridamole, isosorbide mononitrate, and lidoflazine; and those prescribed for the prevention and/or treatment of rheumatic diseases such as rheumatoid arthritis: non-steroidal antiinflammatory drugs (NSAIDs) and steroidal antiinflammatory drugs such as diclofenac sodium, ibuprofen, ketoprofen, diflunisal, piroxicam, motrin, and naproxen, and combinations thereof.
- The active agent of the present invention also preferably includes drugs that are subject to the first pass effect. Various examples of such drugs include (but are not limited to) acetaminophen, aldosterone, alprenolol, amitryptyline, aspirin, beclomethasone, diproprionate, bromocriptine, butorphanol tartrate, chlormethiazole, chlorpheniramine, chlorpromazine HCl, cimetidine, codeine, cortisone, cyclobenzamine HCl, desmethylimipramine, dextropropoxyphene, dihydroergotamine, diltiazem HCl, dobutamine HCl, domperidone, dopamine HCl, doxepin HCl, epinephrine, ergoloid mesylates, ergotamine tartrate estradiol, ethinylestradiol, flunisolide, fluorouracil, flurazepam HCl, 5-fluoro-21-deoxyuridine, furosemide, glipizide, glyburide, glyceryl trinitrate, guanethidine sulfate, hydralazine HCl, imipramine HCl, indoramin, isoethorine HCl, isoethrine mesylate, isoprenaline, isoproterenol sulfate, isosorbide dinitrate, levallorphan tartrate, levodopa, lidocaine HCl, lignocaine, lorcainide, meperidine HCl, 6-mercaptopurine, metaproterenol sulfate, methoxamine HCl, methylphenidate, methylpreonisolone, methyltestosterone mesylate, metoclopramide, metoprolol tartrate, morphine sulfate, nalbuphine HCl, naloxone HCl, neostigmine, nifedipine, nitrendipine, nitroglycerin, norepinephrine bitartrate, norethindrone, nortriptylene HCl, oxprenolol, oxyphenbutazone, penicillamine, pentazocine HCl, pentazocine lactate, pentobarbital, petnidine, phenacetin, phentolamine HCl, phentolamine mesylate, phenylephrine HCl, phenylephrine bitartrate, phenytoin, pindolal, prazosin, prednisone, progesterone, propoxyphene HCl, propoxyphene napsylate, propranolol HCl, quinidine, reserpine, ritodrine HCl, salicylamide, salbutamol, secobarbital, testosterone, terbutaline, timolol maleate, tolbutamide, and verapamil HCl.
- In a preferred embodiment of the present invention, the active agent may include the drug, isosorbide-5-mononitrate, an organic nitrate, which is a vasodilator with effects on both arteries and veins. The empirical formula is C6H9NO6 and the molecular weight is 191.14. The chemical name for isosorbide mononitrate is 1,4:3,6-dianhydro-D-glucitrol 5-nitrate.
- Isosorbide mononitrate is the major active metabolite of isosorbide dinitrate and most of the clinical activity of the dinitrate can be attributable to the mononitrate. A principal pharmacological action of isosorbide mononitrate is relaxation of vascular smooth muscle and consequent dilatation of peripheral arteries and veins, especially the latter. Dilatation of the veins is known to promote peripheral pooling of blood and decrease venous return to the heart, thereby reducing left ventricular and diastolic pressure and pulmonary capillary wedge pressure (preload). Arteriolar relaxation reduces systemic vascular resistance, systolic arterial pressure, and mean arterial pressure (afterload). Dilation of the coronary arteries also occurs. The relative importance of preload reduction, afterload reduction, and coronary dilatation remains undefined. The mechanism by which isosorbide mononitrate relieves angina pecteria is not fully understood.
- Isosorbide mononitrate is rapidly and completely absorbed from the gastrointestinal tract. In humans, isosorbide mononitrate is not subject to first pass metabolism in the liver. The overall elimination half-life of isosorbide mononitrate is about 6 hours. The rate of clearance is the same in healthy young adults, and in patients with various degrees of renal, hepatic, or cardiac dysfunction.
- In accordance with the present invention, the term “polymer” includes single or multiple polymeric substances, which can swell, gel, degrade or erode on contact with an aqueous environment (e.g., water), such as one or more of alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium, colloidal silicon dioxide, guar gum, magnesium aluminum silicate, methylcellulose, microcrystalline cellulose, cellulose, pregelatinized starch, sodium alginate, starch, ethylcellulose, gelatin, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polymethacrylates, povidone, pregelatinized starch, shellac, and zein, and combinations thereof.
- The “hydrophilic polymers” of the present invention include one or more of carboxymethylcellulose, guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose, and povidone. The “hydrophobic materials” of the present invention include one or more of carnauba wax, ethylcellulose, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, microcrystalline wax, polymethacrylates, and stearic acid.
- Without further elaboration, it is believed that one skilled in the art, using the preceding description, can practice the present invention to the fullest extent. The following examples are illustrative only, and not limiting of the remainder of the disclosure in any way whatsoever.
- The method below was employed to obtain a multiplex drug delivery system, the composition of which is set forth in the tables immediately following in Table 1:
- Immediate-Release Compartment. Isosorbide mononitrate was first mixed with silicon dioxide in a Patterson-Kelley V-blender together with microcrystalline cellulose, croscarmellulose sodium, and magnesium stearate for 15 minutes. The powder blend was then compressed using a Manesty Dry-cota with a {fraction (3/16)}″ diameter, round, flat-face punch and die set. The hardness of the tablets were maintained at 4±2 kp.
- Immediate-Release Compartment Plus Extended-Release Compartment Isosorbide mononitrate was mixed with silicon dioxide in a Patterson-Kelley V-blender together with hydroxypropyl methylcellulose 2208, microcrystalline cellulose, hydrogenated vegetable oil, and magnesium stearate for 15 minutes. The core tablets were press-coated using a Korsch Core Coater {fraction (5/16)}″×¾″ capsule shape punches. The hardness of the tablets were maintained at 12±4 kp.
- In addition, the formulation of respective release compartments can occur by appropriate granulation methods. In wet granulation, solutions of the binding agent (polymer) are added with stirring to the mixed powders. The powder mass is wetted with the binding solution until the mass has the consistency of damp snow or brown sugar. The wet granulated material is forced through a sieving device. Moist material from the milling step is dried by placing it in a temperature controlled container. After drying, the granulated material is reduced in particle size by passing through a sieving device. Lubricant is added, and the final blend is then compressed.
- In fluid-bed granulation, particles of inert material and/or active agent are suspended in a vertical column with a rising air stream. While the particles are suspended, the common granulating materials in solution are sprayed into the column. There is a gradual particle buildup under a controlled set of conditions resulting in tablet granulation. Following drying and the addition of lubricant, the granulated material is ready for compression.
- In dry-granulation, the active agent, diluent, and lubricant are blended and compressed into large tablets. The compressed large tablets are comminuted through the desirable mesh screen by sieving equipment. Some more lubricant is added to the granulated material and blended gently. The material is then compressed into tablets.
TABLE 1 QUANTITY/ TABLET Example # 1 Example # 2Immediate-Release (IR) Compartment Lot 127-13 Lot 127-13 Isosorbide-5- mononitrate 80% w/lactose25.0 mg 25.0 mg Croscarmellose sodium 1.1 mg 1.1 mg Microcrystalline cellulose 28.2 mg 28.2 mg Colloidal silicon dioxide 0.2 mg 0.2 mg Magnesium stearate 0.5 mg 0.5 mg Total: 55.0 mg 55.0 mg IR Compartment Plus Extended-Release (ER) Compartment Lot 127-19A Lot 127-19B IR Compartment (two cores) 110.0 mg 110.0 mg Isosorbide-5- mononitrate 80% w/lactose37.5 mg 37.5 mg Hydroxypropyl methylcellulose, type 2208 201.6 mg 288.0 mg Microcrystalline cellulose 245.5 mg 245.5 mg Hydrogenated vegetable oil, type 1223.2 mg 136.8 mg Colloidal silicon dioxide 3.6 mg 3.6 mg Magnesium stearate 7.2 mg 7.2 mg Blue dye 1.4 mg 1.4 mg Total: 830.0 mg 830.0 mg - The invention has been disclosed broadly and illustrated in reference to representative embodiments described above. Those skilled in the art will recognize that various modifications can be made to the present invention without departing from the spirit and scope thereof.
Claims (37)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/435,013 US20030203028A1 (en) | 1998-09-29 | 2003-05-12 | Multiplex drug delivery system suitable for oral administration |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/164,642 US6602521B1 (en) | 1998-09-29 | 1998-09-29 | Multiplex drug delivery system suitable for oral administration |
US10/435,013 US20030203028A1 (en) | 1998-09-29 | 2003-05-12 | Multiplex drug delivery system suitable for oral administration |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/164,642 Continuation US6602521B1 (en) | 1998-09-29 | 1998-09-29 | Multiplex drug delivery system suitable for oral administration |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030203028A1 true US20030203028A1 (en) | 2003-10-30 |
Family
ID=22595418
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/164,642 Expired - Lifetime US6602521B1 (en) | 1998-09-29 | 1998-09-29 | Multiplex drug delivery system suitable for oral administration |
US10/435,013 Abandoned US20030203028A1 (en) | 1998-09-29 | 2003-05-12 | Multiplex drug delivery system suitable for oral administration |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/164,642 Expired - Lifetime US6602521B1 (en) | 1998-09-29 | 1998-09-29 | Multiplex drug delivery system suitable for oral administration |
Country Status (7)
Country | Link |
---|---|
US (2) | US6602521B1 (en) |
EP (1) | EP1416920B1 (en) |
AU (1) | AU6141199A (en) |
DE (1) | DE69934831T2 (en) |
ES (1) | ES2278455T3 (en) |
TW (1) | TWI228997B (en) |
WO (1) | WO2000018447A2 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030119786A1 (en) * | 2001-10-05 | 2003-06-26 | Curtis Keith | Combinations for the treatment of immunoinflammatory disorders |
US20070010502A1 (en) * | 2003-10-15 | 2007-01-11 | Combinatorx Inc. | Methods and reagents for the treatment of immunoinflammatory disorders |
US20070048376A1 (en) * | 2005-08-24 | 2007-03-01 | Penwest Pharmaceuticals Co. | Sustained release formulations of nalbuphine |
US20080003213A1 (en) * | 2006-05-22 | 2008-01-03 | Jan Lessem | Methods and compositions for the treatment of diseases or conditions associated with increased C-reactive protein, interleukin-6, or interferon-gamma levels |
US20090075955A1 (en) * | 2007-09-19 | 2009-03-19 | Combinatorx, Inc. | Therapeutic regimens for the treatment of immunoinflammatory disorders |
US20110189293A1 (en) * | 2007-12-17 | 2011-08-04 | CombinatoRx, Incoporated | Therapeutic regimens for the treatment of immunoinflammatory disorders |
US8765175B2 (en) | 2005-08-24 | 2014-07-01 | Endo Pharmaceuticals Inc | Sustained release formulation of nalbuphine |
US10098845B2 (en) | 2013-10-07 | 2018-10-16 | Impax Laboratories, Llc | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8071128B2 (en) | 1996-06-14 | 2011-12-06 | Kyowa Hakko Kirin Co., Ltd. | Intrabuccally rapidly disintegrating tablet and a production method of the tablets |
SE9802973D0 (en) | 1998-09-03 | 1998-09-03 | Astra Ab | Immediate release tablet |
US7122143B2 (en) | 2001-09-28 | 2006-10-17 | Mcneil-Ppc, Inc. | Methods for manufacturing dosage forms |
BR0212951A (en) | 2001-09-28 | 2004-10-26 | Mcneil Ppc Inc | Composite Dosage Forms |
US6837696B2 (en) | 2001-09-28 | 2005-01-04 | Mcneil-Ppc, Inc. | Apparatus for manufacturing dosage forms |
US7838026B2 (en) | 2001-09-28 | 2010-11-23 | Mcneil-Ppc, Inc. | Burst-release polymer composition and dosage forms comprising the same |
US9358214B2 (en) | 2001-10-04 | 2016-06-07 | Adare Pharmaceuticals, Inc. | Timed, sustained release systems for propranolol |
US20040265381A1 (en) * | 2001-10-08 | 2004-12-30 | Shanghvi Dilip S. | Anti-asthmatic drug (asmakure) from indigenous herbs to cure the disease asthma |
EP1457204A4 (en) * | 2001-12-19 | 2007-11-14 | Sanwa Kagaku Kenkyusho Co | Release control type formed product |
CA2500312A1 (en) * | 2002-09-28 | 2004-04-08 | Mcneil-Ppc, Inc. | Modified release dosage form |
NZ538842A (en) * | 2002-09-28 | 2008-03-28 | Mcneil Ppc Inc | Immediate release dosage form comprising a solid core of density 0.9 g/ml surrounded by a shell that is readily soluble to gastrointestinal fluids |
US7807197B2 (en) | 2002-09-28 | 2010-10-05 | Mcneil-Ppc, Inc. | Composite dosage forms having an inlaid portion |
US7988993B2 (en) | 2002-12-09 | 2011-08-02 | Andrx Pharmaceuticals, Inc. | Oral controlled release dosage form |
US8367111B2 (en) * | 2002-12-31 | 2013-02-05 | Aptalis Pharmatech, Inc. | Extended release dosage forms of propranolol hydrochloride |
PT1631251E (en) | 2003-04-24 | 2011-09-19 | Jagotec Ag | Delayed release tablet with defined core geometry |
US9492541B2 (en) * | 2004-09-14 | 2016-11-15 | Sovereign Pharmaceuticals, Llc | Phenylepherine containing dosage form |
KR20100045528A (en) * | 2004-04-01 | 2010-05-03 | 테바 파마슈티컬 인더스트리즈 리미티드 | Delayed release formulations of 6-mercaptopurine |
US8188067B2 (en) * | 2004-04-01 | 2012-05-29 | Teva Pharmaceutical Industries Ltd. | Formulations of 6-mercaptopurine |
SE0401031D0 (en) * | 2004-04-22 | 2004-04-22 | Duocort Ab | A new glucocorticoid replacement therapy |
JP5395355B2 (en) * | 2004-05-21 | 2014-01-22 | アキュ−ブレイク テクノロジーズ インコーポレーテッド | Pharmaceutical tablet containing two or more unit segments |
EP1761231A1 (en) * | 2004-06-07 | 2007-03-14 | Duramed Pharmaceuticals, Inc. | Dispenser for progestin used for acute and maintenance treatment of dub |
US8747895B2 (en) | 2004-09-13 | 2014-06-10 | Aptalis Pharmatech, Inc. | Orally disintegrating tablets of atomoxetine |
US9884014B2 (en) | 2004-10-12 | 2018-02-06 | Adare Pharmaceuticals, Inc. | Taste-masked pharmaceutical compositions |
AU2005299490C1 (en) | 2004-10-21 | 2012-01-19 | Adare Pharmaceuticals, Inc. | Taste-masked pharmaceutical compositions with gastrosoluble pore-formers |
US8383159B2 (en) | 2004-10-27 | 2013-02-26 | Mcneil-Ppc, Inc. | Dosage forms having a microreliefed surface and methods and apparatus for their production |
US8673352B2 (en) | 2005-04-15 | 2014-03-18 | Mcneil-Ppc, Inc. | Modified release dosage form |
US9161918B2 (en) | 2005-05-02 | 2015-10-20 | Adare Pharmaceuticals, Inc. | Timed, pulsatile release systems |
AU2006280656B2 (en) * | 2005-08-18 | 2012-09-20 | Teijin Limited | Preparation with accurate dose-dividing function |
AU2007211101B2 (en) * | 2006-01-27 | 2013-05-02 | Adare Pharmaceuticals, Inc. | Drug delivery systems comprising weakly basic drugs and organic acids |
ES2550035T3 (en) * | 2006-01-27 | 2015-11-04 | Adare Pharmaceuticals, Inc. | Drug delivery systems comprising a weakly basic serotonin 5-HT3 selective blocking agent and organic acids |
US20070190141A1 (en) * | 2006-02-16 | 2007-08-16 | Aaron Dely | Extended release opiate composition |
NZ573174A (en) * | 2006-06-01 | 2012-01-12 | Msd Consumer Care Inc | Sustained release pharmaceutical dosage form containing phenylephrine |
ES2391585T3 (en) * | 2006-06-01 | 2012-11-28 | Msd Consumer Care, Inc. | Sustained release pharmaceutical formulation comprising phenylephrine |
CN104606163A (en) * | 2006-06-01 | 2015-05-13 | 默沙东公司 | Pharmaceutical compositions for sustained release of phenyephrine |
RU2008151945A (en) * | 2006-06-01 | 2010-07-20 | Шеринг Корпорейшн (US) | PULSE-RELEASE DOSAGE FORMS AND PHENYLEFRIN PHARMACEUTICAL COMPOSITIONS |
WO2007149860A1 (en) * | 2006-06-19 | 2007-12-27 | Accu-Break Technologies, Inc. | Segmented pharmaceutical dosage forms |
EA015304B1 (en) | 2006-08-03 | 2011-06-30 | Нитек Фарма Аг | Delayed-release glucocorticoid treatment of rheumatoid disease |
US20080075766A1 (en) * | 2006-09-25 | 2008-03-27 | Shun-Por Li | Multi-core dosage form having transparent outer coating |
CA2697959A1 (en) * | 2007-06-01 | 2008-12-11 | Schering-Plough Healthcare Products, Inc. | Pharmaceutical composition comprising a substrate and a coating containing an active ingredient and polyvinylalcohol |
CA2694602A1 (en) * | 2007-07-27 | 2009-02-05 | Depomed, Inc. | Pulsatile gastric retentive dosage forms |
PE20091084A1 (en) * | 2007-12-07 | 2009-07-23 | Schering Plough Healthcare | PHARMACEUTICAL FORMULATIONS OF PHENYLPHRINE AND COMPOSITIONS FOR TRANSMUCOSAL ABSORPTION |
US8133506B2 (en) * | 2008-03-12 | 2012-03-13 | Aptalis Pharmatech, Inc. | Drug delivery systems comprising weakly basic drugs and organic acids |
EP2110130A1 (en) * | 2008-04-18 | 2009-10-21 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical use of 6-mercaptopurine |
US20100255082A1 (en) * | 2008-07-31 | 2010-10-07 | Ishwar Chauhan | Functionally Coated Breakable Tablets |
ES2740360T3 (en) * | 2008-08-15 | 2020-02-05 | Assertio Therapeutics Inc | Pharmaceutical gastric retention compositions for the treatment and prevention of CNS disorders |
WO2010084188A1 (en) * | 2009-01-26 | 2010-07-29 | Nitec Pharma Ag | Delayed-release glucocorticoid treatment of asthma |
NZ582836A (en) * | 2009-01-30 | 2011-06-30 | Nitec Pharma Ag | Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage |
US20110003005A1 (en) * | 2009-07-06 | 2011-01-06 | Gopi Venkatesh | Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions |
WO2011005686A1 (en) * | 2009-07-06 | 2011-01-13 | Aptapharma, Inc. | Self-breaking tablets |
CN108159019A (en) | 2009-12-02 | 2018-06-15 | 阿黛尔药物有限公司 | Fexofenadine microcapsules and the composition containing fexofenadine microcapsules |
US20110280936A1 (en) * | 2010-05-17 | 2011-11-17 | Aptapharma, Inc. | Self Breaking Tablets |
US9375437B2 (en) | 2010-06-18 | 2016-06-28 | Lipocine Inc. | Progesterone containing oral dosage forms and kits |
US20110312928A1 (en) * | 2010-06-18 | 2011-12-22 | Lipocine Inc. | Progesterone Containing Oral Dosage Forms and Related Methods |
US8911780B2 (en) * | 2011-02-11 | 2014-12-16 | Zx Pharma, Llc | Multiparticulate L-menthol formulations and related methods |
US8951996B2 (en) | 2011-07-28 | 2015-02-10 | Lipocine Inc. | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
CN105142726B (en) | 2013-04-23 | 2020-02-07 | Zx制药有限责任公司 | Enteric coated multiparticulate composition with proteinaceous subcoating |
US10987313B2 (en) | 2013-10-07 | 2021-04-27 | Impax Laboratories, Llc | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
BR112017027688A2 (en) | 2015-06-22 | 2018-09-04 | Lipocine Inc | ORAL COMPOSITIONS CONTAINING 17- HYDROXYPROGESTERONE ESTER AND RELATED METHODS |
EP3362053A4 (en) | 2015-10-16 | 2019-04-17 | Hadasit Medical Research Services and Development Ltd. | Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine |
CN108968976B (en) | 2017-05-31 | 2022-09-13 | 心脏起搏器股份公司 | Implantable medical device with chemical sensor |
CN109381195B (en) | 2017-08-10 | 2023-01-10 | 心脏起搏器股份公司 | Systems and methods including electrolyte sensor fusion |
CN109419515B (en) * | 2017-08-23 | 2023-03-24 | 心脏起搏器股份公司 | Implantable chemical sensor with staged activation |
CN109864746B (en) | 2017-12-01 | 2023-09-29 | 心脏起搏器股份公司 | Multimode analyte sensor for medical devices |
CN109864747B (en) | 2017-12-05 | 2023-08-25 | 心脏起搏器股份公司 | Multimode analyte sensor optoelectronic interface |
US20210378968A1 (en) * | 2020-05-28 | 2021-12-09 | Johnson & Johnson Consumer Inc. | Multi-cavity customizable dosage forms |
US11071739B1 (en) | 2020-09-29 | 2021-07-27 | Genus Lifesciences Inc. | Oral liquid compositions including chlorpromazine |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4252786A (en) * | 1979-11-16 | 1981-02-24 | E. R. Squibb & Sons, Inc. | Controlled release tablet |
US4353887A (en) * | 1979-08-16 | 1982-10-12 | Ciba-Geigy Corporation | Divisible tablet having controlled and delayed release of the active substance |
US4713248A (en) * | 1984-02-10 | 1987-12-15 | A/S Alfred Benzon | Diffusion coated multiple-units dosage form |
US4892741A (en) * | 1987-06-24 | 1990-01-09 | Bayer Aktiengesellschaft | Press coated DHP tablets |
US5213738A (en) * | 1990-05-15 | 1993-05-25 | L. Perrigo Company | Method for making a capsule-shaped tablet |
US5425950A (en) * | 1991-10-30 | 1995-06-20 | Glaxo Group Limited | Controlled release pharmaceutical compositions |
US5475577A (en) * | 1992-07-07 | 1995-12-12 | Donnelly Corporation | Accessory attachment plate for vehicle panels |
US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
US5500227A (en) * | 1993-11-23 | 1996-03-19 | Euro-Celtique, S.A. | Immediate release tablet cores of insoluble drugs having sustained-release coating |
US5707636A (en) * | 1994-08-03 | 1998-01-13 | Saitec S.R.L. | Apparatus and method for preparing solid forms with controlled release of the active ingredient |
US5788987A (en) * | 1997-01-29 | 1998-08-04 | Poli Industria Chimica Spa | Methods for treating early morning pathologies |
US5849330A (en) * | 1991-09-17 | 1998-12-15 | Orion-Yhtyma Oy | Controlled release pharmaceutical |
US5869094A (en) * | 1993-04-27 | 1999-02-09 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Solid form of administration of isosorbide 5-mononitrate |
US5891474A (en) * | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3336200A (en) * | 1963-05-28 | 1967-08-15 | Warner Lambert Pharmaceutical | Tablet structure |
FR1603314A (en) * | 1965-02-23 | 1971-04-05 | Pharmaceutical tablets - having a core and a matrix material | |
US4894240A (en) | 1983-12-22 | 1990-01-16 | Elan Corporation Plc | Controlled absorption diltiazem formulation for once-daily administration |
FR2585948B1 (en) | 1985-08-06 | 1988-12-16 | Pf Medicament | PROCESS FOR THE MANUFACTURE OF INDOMETACIN TABLETS |
ATE107857T1 (en) * | 1986-06-10 | 1994-07-15 | Euro Celtique Sa | COMPOSITION WITH CONTROLLED RELEASE OF DIHYDROCODEINE. |
US5017381A (en) * | 1990-05-02 | 1991-05-21 | Alza Corporation | Multi-unit pulsatile delivery system |
AU2016992A (en) | 1991-05-20 | 1992-12-30 | Marion Laboratories, Inc. | Multi-layered controlled release formulation |
US5286497A (en) | 1991-05-20 | 1994-02-15 | Carderm Capital L.P. | Diltiazem formulation |
US5395626A (en) | 1994-03-23 | 1995-03-07 | Ortho Pharmaceutical Corporation | Multilayered controlled release pharmaceutical dosage form |
-
1998
- 1998-09-29 US US09/164,642 patent/US6602521B1/en not_active Expired - Lifetime
-
1999
- 1999-09-13 DE DE69934831T patent/DE69934831T2/en not_active Expired - Lifetime
- 1999-09-13 AU AU61411/99A patent/AU6141199A/en not_active Abandoned
- 1999-09-13 EP EP99948182A patent/EP1416920B1/en not_active Expired - Lifetime
- 1999-09-13 WO PCT/US1999/020807 patent/WO2000018447A2/en active IP Right Grant
- 1999-09-13 ES ES99948182T patent/ES2278455T3/en not_active Expired - Lifetime
- 1999-09-14 TW TW088115834A patent/TWI228997B/en not_active IP Right Cessation
-
2003
- 2003-05-12 US US10/435,013 patent/US20030203028A1/en not_active Abandoned
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4353887A (en) * | 1979-08-16 | 1982-10-12 | Ciba-Geigy Corporation | Divisible tablet having controlled and delayed release of the active substance |
US4252786A (en) * | 1979-11-16 | 1981-02-24 | E. R. Squibb & Sons, Inc. | Controlled release tablet |
US4713248A (en) * | 1984-02-10 | 1987-12-15 | A/S Alfred Benzon | Diffusion coated multiple-units dosage form |
US4892741A (en) * | 1987-06-24 | 1990-01-09 | Bayer Aktiengesellschaft | Press coated DHP tablets |
US5213738A (en) * | 1990-05-15 | 1993-05-25 | L. Perrigo Company | Method for making a capsule-shaped tablet |
US5849330A (en) * | 1991-09-17 | 1998-12-15 | Orion-Yhtyma Oy | Controlled release pharmaceutical |
US5425950A (en) * | 1991-10-30 | 1995-06-20 | Glaxo Group Limited | Controlled release pharmaceutical compositions |
US5475577A (en) * | 1992-07-07 | 1995-12-12 | Donnelly Corporation | Accessory attachment plate for vehicle panels |
US5869094A (en) * | 1993-04-27 | 1999-02-09 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Solid form of administration of isosorbide 5-mononitrate |
US5500227A (en) * | 1993-11-23 | 1996-03-19 | Euro-Celtique, S.A. | Immediate release tablet cores of insoluble drugs having sustained-release coating |
US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
US5707636A (en) * | 1994-08-03 | 1998-01-13 | Saitec S.R.L. | Apparatus and method for preparing solid forms with controlled release of the active ingredient |
US5788987A (en) * | 1997-01-29 | 1998-08-04 | Poli Industria Chimica Spa | Methods for treating early morning pathologies |
US5891474A (en) * | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7915265B2 (en) | 2001-10-05 | 2011-03-29 | Zalicus Inc. | Combinations for the treatment of immunoinflammatory disorders |
US20030119786A1 (en) * | 2001-10-05 | 2003-06-26 | Curtis Keith | Combinations for the treatment of immunoinflammatory disorders |
US7253155B2 (en) | 2001-10-05 | 2007-08-07 | Combinatorx, Inc. | Combinations for the treatment of immunoinflammatory disorders |
US20110223621A1 (en) * | 2001-10-05 | 2011-09-15 | Curtis Keith | Combinations for the treatment of immunoinflammatory disorders |
US20070010502A1 (en) * | 2003-10-15 | 2007-01-11 | Combinatorx Inc. | Methods and reagents for the treatment of immunoinflammatory disorders |
US8080553B2 (en) | 2003-10-15 | 2011-12-20 | Zalicus Inc. | Methods and reagents for the treatment of immunoinflammatory disorders |
US9186330B2 (en) | 2005-08-24 | 2015-11-17 | Endo Pharmaceuticals Inc. | Sustained release formulation of nalbuphine |
US8765175B2 (en) | 2005-08-24 | 2014-07-01 | Endo Pharmaceuticals Inc | Sustained release formulation of nalbuphine |
US8771732B2 (en) | 2005-08-24 | 2014-07-08 | Endo Pharmaceuticals Inc | Sustained release formulations of nalbuphine |
US20070048376A1 (en) * | 2005-08-24 | 2007-03-01 | Penwest Pharmaceuticals Co. | Sustained release formulations of nalbuphine |
US9351938B2 (en) | 2005-08-24 | 2016-05-31 | Endo Pharmaceuticals Inc | Sustained release formulation of nalbuphine |
US10172798B2 (en) | 2005-08-24 | 2019-01-08 | Endo Pharmaceuticals Inc. | Sustained release formulation of nalbuphine |
US10406106B2 (en) | 2005-08-24 | 2019-09-10 | Endo Pharmaceuticals Inc. | Sustained release formulations of nalbuphine |
US20080003213A1 (en) * | 2006-05-22 | 2008-01-03 | Jan Lessem | Methods and compositions for the treatment of diseases or conditions associated with increased C-reactive protein, interleukin-6, or interferon-gamma levels |
US20090075955A1 (en) * | 2007-09-19 | 2009-03-19 | Combinatorx, Inc. | Therapeutic regimens for the treatment of immunoinflammatory disorders |
US20110189293A1 (en) * | 2007-12-17 | 2011-08-04 | CombinatoRx, Incoporated | Therapeutic regimens for the treatment of immunoinflammatory disorders |
US10098845B2 (en) | 2013-10-07 | 2018-10-16 | Impax Laboratories, Llc | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
US10292935B2 (en) | 2013-10-07 | 2019-05-21 | Impax Laboratories, Inc. | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
US6602521B1 (en) | 2003-08-05 |
EP1416920B1 (en) | 2007-01-10 |
DE69934831D1 (en) | 2007-02-22 |
AU6141199A (en) | 2000-04-17 |
EP1416920A2 (en) | 2004-05-12 |
WO2000018447A2 (en) | 2000-04-06 |
DE69934831T2 (en) | 2007-08-16 |
ES2278455T3 (en) | 2007-08-01 |
TWI228997B (en) | 2005-03-11 |
WO2000018447A3 (en) | 2004-02-19 |
EP1416920A4 (en) | 2004-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6602521B1 (en) | Multiplex drug delivery system suitable for oral administration | |
US6372254B1 (en) | Press coated, pulsatile drug delivery system suitable for oral administration | |
JP4012689B2 (en) | New sustained-release oral preparation | |
EP0396425B1 (en) | Extended release pharmaceutical formulations | |
JP3950175B2 (en) | Multi-layer penetrating device | |
ES2368066T3 (en) | COMPRESSED DELAYED RELEASE WITH DEFINED NUCLEUS GEOMETRY. | |
JP3955320B2 (en) | Banded extended release active dosage form | |
US20080286344A1 (en) | Solid form | |
DK170110B1 (en) | Slow release pharmaceutical composition and use of fumaric acid to prepare the composition | |
US20060134206A1 (en) | Oral compositions for treatment of diseases | |
US20110071137A1 (en) | Process for preparing sustained release tablets | |
US20080286343A1 (en) | Solid form | |
CA2651890C (en) | Controlled dose drug delivery system | |
PL191692B1 (en) | Method of manufacturing orally administered solid pharmaceutic products with controllable active substance release r | |
JP2003508422A (en) | Controlled release pellet formulation | |
WO2008140460A1 (en) | Solid form | |
MXPA06003101A (en) | Chronotherapeutic dosage forms. | |
WO2008140461A1 (en) | Solid form | |
CN100589793C (en) | Pharmaceutical tablet system that floats on gastric fluid for multipulse release of active substance, the system and the preparation of the enveloping substance of the system | |
JP2003510268A (en) | Oral controlled release formulation | |
JPS6193113A (en) | Durative preparation for oral cavity | |
Rameshgiri | Development and Evaluation of Controlled Release Matrix Tablets of Diltiazem Hydrochloride Using Natural Polymers | |
NO175514B (en) | Method of producing spheres for manufacturing controlled release products | |
MXPA01002365A (en) | New sustained release oral formulations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: IMPAX LABORATORIES, INC., CALIFORNIA Free format text: MERGER CHANGE OF NAME;ASSIGNOR:IMPAX PHARMACEUTICALS, INC.;REEL/FRAME:015251/0467 Effective date: 19991214 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINIS Free format text: SECURITY AGREEMENT;ASSIGNOR:IMPAX LABORATORIES, INC.;REEL/FRAME:026112/0133 Effective date: 20110211 |
|
AS | Assignment |
Owner name: IMPAX LABORATORIES, INC, CALIFORNIA Free format text: RELEASE (REEL 026112/ FRAME 0133);ASSIGNOR:WELLS FARGO BANK;REEL/FRAME:035070/0860 Effective date: 20150211 |